Search All News
In a phase three clinical trial, sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment.
Anil K. Rustgi, MD, an expert in gastrointestinal tumors, will join Columbia University Irving Medical Center and NewYork-Presbyterian as director of the Herbert Irving Comprehensive Cancer Center.
- January 20, 2016
Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
- January 19, 2016
A new targeted therapy for hard-to-treat chronic lymphocytic leukemia appears to have fewer side effects than a previous therapy.
- October 29, 2015
Columbia researchers Andrea Califano and Jean Gautier have received prestigious NCI awards that support and encourage leaders in cancer research.
- October 28, 2015
Columbia has one of six new sites launched by the NIH's Breast Cancer and Environment Research Program for prevention and research across the lifespan.
- October 21, 2015
According to a recent study, a microsurgical approach is found to be a safe and effective technique to prevent breast cancer-related lymphedema.
- October 12, 2015
Andrea Califano and his investigative team discover a molecular signaling mechanism underlying a specific type of highly aggressive breast cancer.
- October 5, 2015
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
- September 23, 2015
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.
- September 18, 2015
Dr. Naiyer Rizvi, director of thoracic oncology at CUMC, offers updates on immune checkpoint inhibitors in certain forms of lung cancers.